Ehren, Rasmus http://orcid.org/0000-0002-3245-7481
Benz, Marcus R.
Brinkkötter, Paul T.
Dötsch, Jörg
Eberl, Wolfgang R.
Gellermann, Jutta
Hoyer, Peter F.
Jordans, Isabelle
Kamrath, Clemens
Kemper, Markus J.
Latta, Kay
Müller, Dominik
Oh, Jun
Tönshoff, Burkhard
Weber, Stefanie
Weber, Lutz T.
,
Funding for this research was provided by:
Universität zu Köln
Article History
Received: 28 April 2021
Accepted: 12 May 2021
First Online: 5 June 2021
Declarations
:
: RE, MRB, BT, and LTW receive financial support from the BMBF (German Ministry of Education and Research) for the implementation of the INTENT study (EudraCT No. 2014-001991-76). RE, PTB, and LTW receive financial support from the DFG (German Research Foundation) for their work within the Clinical Research Unit 329 (“Disease pathways in podocyte injury – from molecular mechanisms to individualized treatment options”) at the University Hospital of Cologne.JD is a consultant and expert for Nestlé Germany AG, Danone S.A., and Novartis Pharma GmbH (Advisory Board).WRE is a consultant and expert at Bayer AG, Biotest AG, and Sobi AG and has received honoraria for lectures from CSL Behring GmbH, Bayer AG, and Novo Nordisk Pharma GmbH.CK is on the scientific advisory board of BioMarin Pharmaceutical Inc., Aegerion Pharmaceuticals GmbH, and Sobi AG and has received honoraria for lectures and training from Aegerion Pharmaceuticals GmbH and Diurnal Ltd.JO is a consultant and reviewer for Alnylam Germany GmbH and Chiesi GmbH (Advisory Board) and has received lecture fees from Recordati Pharma GmbH.BT is a consultant and expert at Bristol-Myers Squibb GmbH. He is on the scientific advisory board of “transplant campus” and conducts clinical studies with the companies Novartis Pharma GmbH and Astellas Pharma GmbH.LTW is a consultant and expert for Alexion-Pharma GmbH, Alnylam Germany GmbH, Greenovation Biotech GmbH, and Chiesi GmbH.JG, PFH, IJ, MJK, KL, DM, and SW declare no conflicts of interest.